Abeona (ABEO) director Leila Alland sells 18,065 shares to cover tax obligations

Rhea-AI Filing Summary

Abeona Therapeutics director Leila Alland reported selling 18,065 shares of common stock on February 2, 2026 at a weighted average price of $5.0906 per share. The sale was made to cover tax obligations from the vesting of restricted stock awards, and she now beneficially owns 173,614 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alland Leila

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		18,065	D	$5.0906(2)	173,614	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Leila Alland	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abeona Therapeutics (ABEO) disclose in this Form 4?

Abeona Therapeutics reported that director Leila Alland sold 18,065 shares of common stock on February 2, 2026. The transaction was executed at a weighted average price of $5.0906 per share, according to the Form 4 filing.

Why did Abeona Therapeutics (ABEO) director Leila Alland sell 18,065 shares?

The filing states the sale was made to cover tax obligations arising from the vesting of restricted stock awards. This indicates the transaction was related to tax withholding on equity compensation rather than an open-market discretionary sale for portfolio reasons.

What price did Abeona Therapeutics (ABEO) shares sell for in Leila Alland’s Form 4 transaction?

The reported sale used a weighted average price of $5.0906 per share. Footnotes explain the shares were sold in multiple trades at prices ranging between $5.09 and $5.12, with detailed trade breakdowns available upon request.

How many Abeona Therapeutics (ABEO) shares does Leila Alland own after this reported sale?

After selling 18,065 shares, director Leila Alland is reported to beneficially own 173,614 shares of Abeona Therapeutics common stock. The Form 4 classifies this remaining ownership as direct, meaning the shares are held in her own name, not through an intermediary entity.

What role does Leila Alland hold at Abeona Therapeutics (ABEO) in this insider filing?

The Form 4 identifies Leila Alland as a director of Abeona Therapeutics Inc. She is not listed as an officer or 10% owner in the report, and the filing is made for one reporting person rather than a group.

Were Leila Alland’s Abeona Therapeutics (ABEO) share sales made in a single trade or multiple trades?

The Form 4 notes that the reported price is a weighted average and the 18,065 shares were sold in multiple transactions. Individual trade prices ranged from $5.09 to $5.12 per share, with full breakdowns available upon request to the company or regulators.